What Evox Therapeutics does

Evox Therapeutics is a privately held, preclinical-stage biotechnology company founded in 2016 as a spinout from the University of Oxford and the Karolinska Institute, headquartered at the Oxford Science Park in Oxford, United Kingdom. The company is developing a proprietary exosome-based delivery platform — branded ExoEdit® — that pairs engineered extracellular vesicles (exosomes) with CRISPR-based gene editing tools to enable safe, redosable, non-viral delivery of genetic medicines into the central nervous system, an area where lipid nanoparticles are largely liver-tropic and adeno-associated viral vectors face immunogenicity, limited cargo capacity, and persistence risks. Supporting technologies include the DeliverEx™ drug-loading platform (using proprietary scaffold proteins TSPAN2 and TSPAN3 that deliver 5–10-fold improvement in cargo loading), Fc-binding extracellular vesicles (Fc-EVs) for antibody-directed tissue targeting, and the engEx-AAV™ technology acquired from Codiak Biosciences in 2023 for AAV-in-exosome delivery.

Evox's wholly owned preclinical pipeline targets genetically validated mechanisms in severe neurodegenerative diseases: MSH3 for Huntington's disease (lead program), ATXN2 for amyotrophic lateral sclerosis and spinocerebellar ataxia type 2, and MECP2 for Rett syndrome (added via a February 2026 collaboration with the Rett Syndrome Research Trust). The company is also exploring cardiovascular applications through an August 2023 research collaboration with the Icahn School of Medicine at Mount Sinai. The intellectual property portfolio covers more than 100 granted patents globally, including US Patent US11,640,272 covering exosome purification methods and four additional manufacturing patents issued in 2022.

Evox is pre-revenue with no commercial products. Its business model is built around retaining worldwide rights to its proprietary programs while pursuing strategic pharmaceutical licensing and co-development partnerships, disease-focused non-profit collaborations (RSRT), and academic research alliances to advance the pipeline toward an IND filing and first-in-human studies targeted for 2027. The company is backed by a syndicate of life-sciences-focused investors including Oxford Science Enterprises, Redmile Group, OrbiMed, GV (Google Ventures), Invus, and Eli Lilly, and has raised approximately $169M in cumulative disclosed equity and grant financing across multiple rounds between 2016 and 2026.

Name

Evox Therapeutics

Legal name

Evox Therapeutics Limited

Website

https://evoxtherapeutics.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

101–250 employees

Short description

Evox Therapeutics is a preclinical Oxford-based biotechnology company developing exosome-based CRISPR gene editing therapies, led by its ExoEdit® platform, for severe neurodegenerative diseases including Huntington's, ALS, SCA2, and Rett syndrome.

Ownership category

akta.pro rank

Product category

Exosome-based Gene Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology/CNS Gene Therapies (HLAAACAH)

akta.pro secondary industries

Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) (HLAAACAD), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

Keywords

• Exosome therapeutics
• Gene editing delivery
• Neurodegenerative disease therapy
• CNS drug delivery
• Extracellular vesicle platform

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Biopharmaceutical Development & Licensing: As a pre-clinical stage biotech company, Evox currently has no revenue. The company is developing a proprietary pipeline of exosome-based gene editing therapies for rare neurodegenerative diseases. Future revenue is expected to derive from licensing deals, co-development agreements, and ultimately commercialization of its therapeutic candidates upon regulatory approval.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Evox Therapeutics develops and engineers exosome-based (extracellular vesicle) delivery vehicles for genetic medicines, pairing proprietary CRISPR-based gene editors with engineered exosomes to safely and potently deliver gene editing therapies to the central nervous system. The company's lead therapeutic candidates target genetically validated disease drivers in Huntington's disease (MSH3), ALS and SCA2 (ATXN2), and Rett syndrome (MECP2), with clinical entry planned for 2027.

Product overview

Evox Therapeutics is a biotechnology company developing a unified platform of exosome-based gene editing therapies. The company's core technology is the ExoEdit® platform, which pairs the natural transport capabilities of exosomes with proprietary CRISPR-based editors to enable safe, redosable delivery of genetic medicines to the central nervous system. Supporting technologies include the DeliverEX drug loading platform for efficient cargo loading and Fc-EV targeting technology for tissue-specific delivery. The proprietary pipeline includes therapeutic programs targeting MSH3 for Huntington's disease, ATXN2 for ALS and SCA2, and MECP2 for Rett syndrome, all at preclinical stage with clinical entry planned for 2027.

Differentiator

Problem solved

Functional benefit

Brands

• ExoEdit: Proprietary genome-editing technology platform that harnesses the natural delivery power of exosomes to precisely deliver CRISPR-based editing tools into specific organs and cells.

Products and services

• ExoEdit® Genome Editing Platform Proprietary genome-editing technology that harnesses the natural delivery capabilities of exosomes to precisely deliver CRISPR-based editing tools into specific organs and cells, including the central nervous system. Designed to enable safer, more effective, and redosable genetic medicines than LNP or viral vector approaches.
• Huntington's Disease Program (MSH3) Preclinical gene editing therapeutic candidate designed to address the root genetic cause of Huntington's disease by targeting the MSH3 gene to stabilize CAG repeat expansions, with the goal of halting disease progression in approximately 70,000 patients across the U.S. and Western Europe.
• ALS Program (ATXN2) Preclinical gene editing therapeutic candidate designed to address ALS by targeting the ATXN2 gene to prevent TDP-43 protein pathology, which underlies 97% of ALS cases, with the goal of stopping disease progression and preserving remaining motor neuron function.
• SCA2 Program (ATXN2) Preclinical gene editing therapeutic candidate targeting ATXN2 gene expansions to halt or reverse disease progression in Spinocerebellar Ataxia Type 2 (SCA2), a rare autosomal dominant neurodegenerative disorder typically manifesting in mid-adulthood, with no cure and only symptomatic management available.
• Rett Syndrome Program (MECP2) Preclinical gene editing therapeutic candidate using the ExoEdit® platform to restore functional MECP2 expression in the central nervous system, addressing the root genetic cause of Rett syndrome caused by pathogenic loss-of-function variants in the X-linked MECP2 gene. Developed in partnership with the Rett Syndrome Research Trust.

Quantifiable outcome

• 10X gene editing efficiency compared to leading non-viral platforms in mouse models
• +4 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and strategic.

• Rett Syndrome Research Trust (RSRT)coreStrategic or Co-development Partner · 26 February 2026Evox partnered with RSRT to assess whether its ExoEdit® exosome-based delivery platform can enable gene editing treatments for Rett syndrome, a severe neurodevelopmental disorder caused by MECP2 gene mutations. The collaboration aims to address the key challenge of safely delivering gene editing therapies to the CNS. Successful findings could establish a preclinical program targeting the majority of Rett syndrome patients. RSRT awarded $1.8 million specifically for non-viral delivery approaches including Evox's engineered exosome technology, and RSRT's $40M Roadmap to Cures initiative (2024) funds this collaboration.
• Icahn School of Medicine at Mount SinaistrategicStrategic or Co-development Partner · 4 August 2023Evox entered a research collaboration and option agreement with Icahn Mount Sinai to develop exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology for improving treatments for heart disease. The collaboration combines Evox's exosome technology with Mount Sinai's deep understanding of gene delivery and cardiovascular research. The exoAAV technology has demonstrated ability to improve in vivo delivery to cardiomyocytes even in the presence of high levels of neutralizing anti-AAV antibodies.
• Codiak BiosciencescoreOEM/ Whitelabel/ Licensing Partner · 20 June 2023Evox acquired Codiak Biosciences' engEx-AAV™ technology platform, including all intellectual property rights and exclusive access to certain engineering and manufacturing rights. This technology enables active loading of AAV into exosomes followed by release upon delivery into recipient cells, improving AAV delivery, increasing expression breadth in preclinical models, and shielding AAVs from neutralizing antibodies. This acquisition further strengthens Evox's dominant intellectual property portfolio.
• Oxford University / Oxford University InnovationcoreStrategic or Co-development Partner · 1 January 2016Evox was founded in 2016 as a spinout from Oxford University, with roots firmly grounded in Oxford University and the Karolinska Institute. The company leverages a world-leading academic and collaborative ecosystem. Key scientific co-founders include Prof. Matthew Wood of University of Oxford who pioneered exosome therapeutics by bioengineering exosomes for RNA delivery in the brain.
• Karolinska InstitutetcoreStrategic or Co-development Partner · 1 January 2016Evox was founded in 2016 as a spinout from the Karolinska Institute. Co-founder Prof. Samir El Andaloussi leads the exosome research group at Karolinska Institutet's Department of Laboratory Medicine. He is a pioneer in extracellular vesicle-based drug delivery, having characterised exosome biology and engineered novel exosome platforms for macromolecule-based therapies targeting neurodegenerative and neuromuscular diseases.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Codiak BioSciences: Was the leading independent exosome therapeutics company before winding down; Evox acquired its engEx-AAV platform in 2023, making Codiak the most directly comparable prior peer in engineered exosome therapeutics for gene delivery.
• Capricor Therapeutics: Clinical-stage biotech developing exosome-based therapeutics (dermaseptin/StealthX platform) for inflammatory and rare diseases; the only other listed exosome-therapeutics peer with human clinical experience and a directly analogous delivery-platform thesis.

Broad incumbents

• CRISPR Therapeutics: Leading commercial-stage CRISPR/Cas9 gene editing company (Casgevy approved); Evox's ExoEdit platform is an exosome-enabled CRISPR delivery system, and CRISPR Therapeutics' Douglas Treco sits on Evox's board, signaling direct technical overlap.
• Intellia Therapeutics: Clinical-stage in vivo CRISPR/Cas9 leader using LNP delivery; directly comparable as the leading non-viral CRISPR delivery competitor to Evox's exosome approach, with programs in transthyretin amyloidosis and HAE.
• Editas Medicine: Clinical-stage CRISPR gene editing company with both in vivo (LNP) and ex vivo (ex vivo edited HSC) programs; comparable as a competitor in CNS-relevant editing (e.g., LCA10 retinal program) targeting similar patient populations to Evox's rare disease pipeline.
• Beam Therapeutics: Clinical-stage base editing company with LNP-based in vivo delivery; comparable as a next-generation editing platform competitor targeting similar CNS, liver and rare disease indications with non-viral delivery.
• uniQure: Commercial-stage gene therapy company (Hemgenix approved) with CNS AAV programs including Huntington's disease (AMT-130); the most direct AAV-based CNS competitor to Evox's MSH3 program in Huntington's.
• Denali Therapeutics: Clinical-stage biotech focused on neurodegeneration with proprietary delivery platforms (e.g., enzyme transport vehicle/OTV) to cross the blood-brain barrier; comparable as a BBB-penetrating CNS therapeutic delivery competitor.
• Voyager Therapeutics: Clinical-stage AAV gene therapy company with CNS programs including Huntington's disease and ALS SOD1; comparable as a leading AAV-based CNS gene therapy competitor with established platform partnerships (e.g., Pfizer, Novartis).

Emerging players

• Lexeo Therapeutics: Clinical-stage AAV gene therapy company with CNS pipeline including APOE4 Alzheimer's and Friedreich's ataxia; comparable as an emerging CNS-focused gene therapy peer pursuing overlapping CNS indications with novel delivery approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/evox-therapeutics-ltd
• Xx.com/evox_ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds6 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evox Therapeutics